AptarGroup: Hold Rating Justified by Solid Pharma Performance Amidst Growth and Margin Challenges
Aptar Pharma Celebrates North America Capacity Expansion
Express News | Aptar’s N-Sorb Nitrosamine Mitigation Solution Accepted to US Fda’s Emerging Technology Program
Aptar's N-Sorb Nitrosamine Mitigation Solution Accepted to US FDA's Emerging Technology Program
Calculating The Intrinsic Value Of AptarGroup, Inc. (NYSE:ATR)
How Is The Market Feeling About AptarGroup?
Return Trends At AptarGroup (NYSE:ATR) Aren't Appealing
Aptargroup Insider Sold Shares Worth $500,338, According to a Recent SEC Filing
Aptar Pharma Enters Into Exclusive Agreement With Pulmotree to Develop and Promote Kolibri Non-Propellant Liquid Inhaler Platform
Aptar Digital Health Announces Asthma Clinical Study With Guy's and St Thomas' NHS Foundation Trust
Insider Sale: Segment President Marc Prieur Sells 3,500 Shares of AptarGroup Inc (ATR)
NYSE New 52-Week Highs And Lows
Zacks Industry Outlook Highlights Packaging Corporation of America, Brambles, AptarGroup and Greif
AptarGroup Hits 52-Week High: What's Driving the Stock's Performance?
AptarGroup(ATR.US) Officer Sells US$7.42 Million in Common Stock
$AptarGroup(ATR.US)$ Officer Kuhn Robert sold 49,463 shares of common stock on Aug 23, 2024 at an average price of $149.9726 for a total value of $7.42 million.Source: Announcement What is statement
Form 144 | AptarGroup(ATR.US) Officer Proposes to Sell 7.42 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Aug 23, $AptarGroup(ATR.US)$ Officer ROBERT W KUHN intends to sell 49,463 shares of its common stock on Aug 23, with a total market value of approximately $7.42 million.
Investors in AptarGroup (NYSE:ATR) Have Seen Returns of 30% Over the Past Five Years
AptarGroup, Inc.'s (NYSE:ATR) Stock Has Fared Decently: Is the Market Following Strong Financials?
Aptargroup Insider Sold Shares Worth $1,054,974, According to a Recent SEC Filing
Aptar's Nasal Unidose System to Deliver Neffy (Epinephrine Nasal Spray), the First and Only FDA-Approved Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis